1st TRANSCAN-3 Joint Call 2021

Basic Information

JTC 2021: Next generation cancer immunotherapy: targeting the tumour microenvironment

Network

TRANSCAN-3

Website

https://transcan.eu/opencall.html

Aim of the joint call

Despite advances in immunotherapies, obstacles and challenges, including limited response rates, the inability to predict clinical efficacy, and potential side effects such as autoimmune reactions or cytokine release syndromes, remain and hinder further applications of immunotherapies in clinics. Thus, a deeper understanding of the TME, able to dissect distinct classes and subclasses of it, is essential for deciphering new mechanisms of immunotherapies, defining new predictive biomarkers, and identifying novel therapeutic targets. In the context of translational research, this topic at the intersection of laboratory and clinical research in immuno-oncology will comprise two general aims: Aim 1: Identification and validation of TME subclasses and their contribution to the resistance mechanisms: Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients. Aim 2: Targeting TME to improve efficacy of immunotherapy in human patients.

Type of joint call

Two Stages - Call with pre-proposals and full proposals submissions

Events

-                                                Launch date
+/04/2021
-                                                Deadline Pre-Proposal
+/06/2021 Submitted proposal: 161
-                                                Deadline Full-Proposal
+/12/2021 Submitted proposal: 56
-                                                Evaluation End Date
+/05/2022
                                                Successful proposal: 20
                                                Proposals funded: 20

Is call co-funded?

Yes

Call follow up funding

There are mechanisms in place to monitor

Call reasons

Achieving critical mass
Sharing competences and associated work
Addressing global issues
Developing common administrative procedures
Access to expertise from different countries

Research fields

Health

Type of research

Applied Research

Target groups

Higher Education Institutions (HEIs)
Public Research Organisations (PROs)
Private and Semi-private Research and Technology Organisations (RTOs)
SME (Small and Medium Enterprises)

Participating networks

n/a

Organisations Participating

Show on map

Country	Organisation
Austria	Austrian Science Fund (FWF)
Belgium	National Fund for Scientific Research (FNRS)
Belgium	Research Foundation Flanders (FWO)
Canada	Canadian Institutes of Health Research (CIHR)
Estonia	Estonian Science Foundation (ETAG)
France	ARC French foundation for Cancer Research (ARC-France)
France	National Cancer Institute (INCa)
Germany	Federal Ministry of Education and Research (BMBF)
Hungary	National Research, Development and Innovation Office (NKFIH)
Ireland	Health Research Board (HRB)
Israel	Ministry of Health (CSO-MOH)
Italy	Alliance Against Cancer (ACC)
Italy	Ministry for Universities and Research (MUR)
Italy	Ministry of Health (MOH/MDS)
Italy	REGIONAL FOUNDATION FOR BIOMEDICAL RESEARCH (FRRB)
Italy	Tuscany Region (TOS)
Latvia	State Education Development Agency (VIAA)
Norway	Norwegian Cancer Society (NCS)
Norway	Research Council of Norway (RCN)
Poland	National Centre for Research and Development (NCBiR)
Portugal	Foundation for Science and Technology (FCT)
Romania	Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI)
Slovakia	Slovak Academy of Science (SAS/SAV)
Spain	Foundation for Asturias Promotion of Applied Scientific Research and Technology (FICYT)
Spain	Institute of Health Carlos III (ISCIII)
Spain	Spanish Association Against Cancer Scientific Foundation (AECC FC)
Taiwan	National Science and Technology Council / Ministry of Science and Technology (NSTC / MoST Taiwan)
Türkiye	The Scientific and Technological Research Council of Turkey (TUBITAK)

Funded Projects

Acronym	Title	No. partners
ANEMONE	The ANswer within the microEnvironment: Malignant pleural me...	5
BIALYMP	Bispecific antibodies in Lymphoma: Microenvironmental profil...	6
CHRYSALIS	Characterization of stromal and innate lymphoid cell populat...	3
IMMOSCAN	The role of IMMune OSteoclasts in CANcer – Implications for ...	5
ImmuMet	Invigorating immunity against brain metastases in lung and b...	5
LipidMac	Exploiting lipid-laden macrophages to overcome resistance to...	4
MAGNOLIA	MAppinG adaptatioN Of tripLe negative breast cancer microenv...	6
PERIMMUNE	Intraperitoneal immune modulation for colorectal peritoneal ...	6
PIXEL	Profiling and functional analysis of the Immune environment ...	6
PREDICO	Defining Predictive Immunedeterminants of response to neoadj...	4
Pur-Ther	New immunotherapies targeting the key purinergic checkpoints...	6
RISEBrain	Reverting immune suppression to elicit brain metastasis cont...	6
SmartCAR-T	SmartCAR-T - Reprogramming of the tumor microenvironment wit...	6
TALETE	TArgeting acute myeloid Leukemia immunosuppressive microEnvi...	6
TANGERINE	Artificial-intelligence-based end-to-end prediction of cance...	6
TENACITY	TargEting the Nectin fAmily to boost Cancer ImmuniTY	6
TRanSLIT	Targeting ROBOs and SLIT guidance cues in the immunosuppress...	6
TumorOUT	Innovative mRNA vaccine against NSCLC: Designing a platform ...	6
UCIPredict	Circulating tumour microenvironment components as Urothelial...	3
iParaCyts	Understanding and therapeutically exploiting the immunosuppr...	6